Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 3
2010 2
2011 1
2012 3
2013 2
2015 1
2016 5
2017 4
2018 8
2019 2
2020 5
2021 4
2022 5
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Mondor's Disease.
Ito H, Ishibashi S, Kaburagi T. Ito H, et al. Among authors: kaburagi t. Intern Med. 2019 Jun 15;58(12):1805. doi: 10.2169/internalmedicine.2024-18. Epub 2019 Feb 25. Intern Med. 2019. PMID: 30799346 Free PMC article. No abstract available.
Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321.
Kasai T, Mori K, Nakamura Y, Seki N, Ichikawa Y, Saito H, Kondo T, Nishikawa K, Otsu S, Bessho A, Tanaka H, Yamaguchi H, Kaburagi T, Imai H, Mori K, Ohtake J, Okamoto H. Kasai T, et al. Among authors: kaburagi t. Cancer Med. 2023 Jul;12(14):14988-14999. doi: 10.1002/cam4.6135. Epub 2023 May 24. Cancer Med. 2023. PMID: 37226421 Free PMC article. Clinical Trial.
Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer.
Shiozawa T, Numata T, Tamura T, Endo T, Kaburagi T, Yamamoto Y, Yamada H, Kikuchi N, Saito K, Inagaki M, Kurishima K, Funayama Y, Miyazaki K, Koyama N, Furukawa K, Nakamura H, Kikuchi S, Ichimura H, Sato Y, Sekine I, Satoh H, Hizawa N. Shiozawa T, et al. Among authors: kaburagi t. Anticancer Res. 2022 May;42(5):2583-2590. doi: 10.21873/anticanres.15736. Anticancer Res. 2022. PMID: 35489768
Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study.
Okauchi S, Numata T, Nawa T, Ichimura H, Saito T, Hayashihara K, Yamada H, Satoh H, Endo T, Inage Y, Kaburagi T, Kiyoshima M, Yamada Y, Tamura T, Saito K, Inagaki M, Hizawa N, Sato Y, Shiozawa T, Sekine I, Ishikawa H, Kurihima K, Sakai M, Kamiyama K, Kimura M, Kikuchi N, Nakamura H, Furukawa K, Kodama T, Miyazaki K, Yamashita T, Hayashi S, Funayama Y, Nomura A. Okauchi S, et al. Among authors: kaburagi t. Anticancer Res. 2020 Feb;40(2):957-964. doi: 10.21873/anticanres.14029. Anticancer Res. 2020. PMID: 32014940
F-18 FDG PET/CT in relapsing polychondritis.
Sato M, Hiyama T, Abe T, Ito Y, Yamaguchi S, Uchiumi K, Hashimoto I, Kaburagi T. Sato M, et al. Among authors: kaburagi t. Ann Nucl Med. 2010 Nov;24(9):687-90. doi: 10.1007/s12149-010-0406-6. Epub 2010 Aug 25. Ann Nucl Med. 2010. PMID: 20737256
Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice.
Yamada Y, Tamura T, Yamamoto Y, Ichimura H, Hayashihara K, Saito T, Yamada H, Endo T, Nakamura R, Inage Y, Satoh H, Iguchi K, Saito K, Inagaki M, Kikuchi N, Kurishima K, Ishikawa H, Sakai M, Kamiyama K, Shiozawa T, Hizawa N, Sekine I, Sato Y, Funayama Y, Miyazaki K, Kodama T, Hayashi S, Nomura A, Nakamura H, Furukawa K, Yamashita T, Okubo H, Suzuki H, Kiyoshima M, Kaburagi T. Yamada Y, et al. Among authors: kaburagi t. Anticancer Res. 2020 Oct;40(10):5757-5764. doi: 10.21873/anticanres.14592. Anticancer Res. 2020. PMID: 32988903 Clinical Trial.
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Masubuchi K, Imai H, Wasamoto S, Tsuda T, Minemura H, Nagai Y, Yamada Y, Kishikawa T, Umeda Y, Shiono A, Takechi H, Shiihara J, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Kagamu H, Minato K. Masubuchi K, et al. Among authors: kaburagi t. Thorac Cancer. 2022 Oct;13(19):2776-2785. doi: 10.1111/1759-7714.14621. Epub 2022 Sep 5. Thorac Cancer. 2022. PMID: 36062426 Free PMC article.
A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632.
Noro R, Igawa S, Bessho A, Hirose T, Shimokawa T, Nakashima M, Minato K, Seki N, Tokito T, Harada T, Sasada S, Miyamoto S, Tanaka Y, Furuya N, Kaburagi T, Hayashi H, Iihara H, Okamoto H, Kubota K. Noro R, et al. Among authors: kaburagi t. Lung Cancer. 2021 Nov;161:49-54. doi: 10.1016/j.lungcan.2021.08.007. Epub 2021 Aug 31. Lung Cancer. 2021. PMID: 34536731 Clinical Trial.
45 results